Insider trade

Director purchased ~$2.2K of VTRS shares in the open market

Traded Nov 3, 2025 · Filed Mar 10, 2026

~$2.2K
Reported value · 213 sh @ $10.4255: 1,183
Holds after · shares reported: +65.8%
stock since the trade · S&P 500 +11.8%, $10.53 → $17.46 on Oct 1

Why it stands out

A board member of Viatris spent $2.2K of their very own money to buy Viatris shares. Their pile of Viatris shares grew by 22%.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 3, 2025
Reporting period: Not applicable
Filed with the SEC: Mar 10, 2026

DirectorIndirect holding<$25KHoldings +22%

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$2,221

Shares × reported transaction price

Size band

<$25K

Ownership change

+22.0%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

First purchase in 3 months

Confirmed open-market purchases by the same insider in the available history

Largest by this insider

No

Compared with 1 earlier confirmed purchase

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Timing vs results

88 days after results of Aug 7, 2025, 3 days before results of Nov 6, 2025

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $10.53 on Nov 3, 2025, 45% above its 52-week low and 21% below its high, after an 8% rise over the previous 30 trading days

52-week range $7.26 (Apr 10, 2025) to $13.37 (Nov 22, 2024), 54% of the way up, from 250 adjusted closes. 30 trading days earlier: $9.79 on Sep 22, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Linagliptin on Nov 3, 2025, the same day as this trade.

Generic drug approved. Active ingredient: Linagliptin. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.6%	-2.2%	+0.6%
30 days	-3.6%	+0.5%	-4.0%
90 days	+16.0%	+9.0%	+7.0%
180 days	+18.9%	+13.3%	+5.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0001140361-26-008886
Filed / recorded: Mar 10, 2026, 11:03 PM UTC
Added to OQRO: Oct 2, 2026, 12:29 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Viatris Inc
Issuer CIK: 1792044
Ticker: VTRS
Reporting person: David S Simmons
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 3, 2025
Transaction code: P
Shares / units: 213
Price per share: $10.4255
Acquired / disposed: Acquired (A)
Shares owned after: 1,183
Ownership form: Indirect — By Family Trusts
Amendment: No

Footnotes from the filing

These shares were acquired by the reporting person's investment advisors in managed accounts as part of the investment advisors' implementation and continued execution of managed investment strategies to mirror certain index funds involving the securities of multiple issuers.
Based on information provided by the investment advisor; additional information, including the price range, if any, is unavailable.
These shares are held in family trusts for which the reporting person or his spouse serve as trustee: (i) 13 shares in a trust for the benefit of the reporting person for which the reporting person serves as trustee; (ii) 63 shares in a trust for the benefit of the reporting person and his children for which the reporting person serves as trustee; (iii) 522 shares in a trust for the benefit of the reporting person's spouse for which the reporting person's spouse serves as trustee; and (iv) 585 shares in trusts for the benefit of the reporting person's children for which the reporting person's spouse serves as trustee.